NewsPiramal Pharma's Sellersville Facility Receives US FDA Form-483 with Three Observations Following GMP InspectionPiramal Pharma's Sellersville Facility Receives US FDA Form-483 with Three Observations Following GMP Inspection
Piramal Pharma Limited disclosed that the US FDA conducted a GMP inspection of its Sellersville, USA facility from 4th May, 2026 to 8th May, 2026, resulting in a Form-483 with three observations. The inspectors recommended a VAI (Voluntary Action Indicated) classification at the closing meeting, and none of the observations relate to data integrity. The company is preparing a detailed response to be submitted to the US FDA within stipulated timelines and has reaffirmed its commitment to maintaining compliance standards.
*this image is generated using AI for illustrative purposes only.
Piramal Pharma Limited has disclosed, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the US Food and Drug Administration (US FDA) conducted a Good Manufacturing Practices (GMP) inspection at its Sellersville, USA facility. The inspection took place from 4th May, 2026 to 8th May, 2026, and concluded with the issuance of a Form-483 carrying three observations.
Inspection Outcome and Key Details
The following table summarises the key details of the US FDA inspection and its outcome:
| Parameter: | Details |
|---|---|
| Facility: | Sellersville, USA |
| Inspection Period: | 4th May, 2026 to 8th May, 2026 |
| Document Issued: | Form-483 |
| Number of Observations: | Three |
| Recommended Classification: | VAI (Voluntary Action Indicated) |
| Data Integrity Issues: | None |
At the closing meeting, the inspectors recommended that the observations be classified under Voluntary Action Indicated (VAI), which is generally considered a less critical classification in the US FDA's inspection outcome framework. The company confirmed that none of the three observations are related to data integrity.
Company's Response and Compliance Commitment
Piramal Pharma stated that it is preparing a detailed response to the observations, which will be submitted to the US FDA within the stipulated timelines. The company reaffirmed its commitment to maintaining the highest standards of compliance and indicated it will work closely with the agency to comprehensively address all the observations.
The disclosure was made by Maneesh Sharma, Company Secretary and Compliance Officer of Piramal Pharma Limited, and was digitally signed on 10th May, 2026.
Historical Stock Returns for Piramal Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.11% | +11.11% | +27.52% | -9.69% | -15.82% | -3.07% |
How might the FDA's final classification of the Sellersville facility inspection impact Piramal Pharma's ability to secure new US drug contracts or expand its CDMO business in North America?
If the FDA upgrades the classification from VAI to OAI after reviewing Piramal's response, what would be the potential financial and operational consequences for the company's US operations?
How does this inspection outcome compare to Piramal Pharma's historical FDA inspection track record across its other global manufacturing facilities, and what does it signal about the company's overall compliance trajectory?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
